Background
• Although it is a rare skin disease, pemphigus foliaceus (PF) is the most common form of pemphigus and probably the most common cutaneous autoimmune disease in the dog. The goal of this study is to assess the efficacy of a Bruton’s Tyrosine Kinase inhibitor (BTKi) as a therapy for canine pemphigus foliaceus.

Participation Requirements
• Dogs weighing over 15 pounds (6.8 kilograms) that are suspected of having or have been previously diagnosed with PF that are naïve to treatment

Procedures
• We will perform a skin biopsy using a local anesthetic (under sedation if needed) or review the histopathology report of a previously collected biopsy to confirm PF diagnosis
• If the biopsy test results have confirmed the diagnosis of PF and you agree to let your dog participate in this study, procedures include:
  • **Day 1:** A physical examination, urine collection and photographs of the lesions. This visit will require a serial blood draw to examine the drug levels in the body over a 24-hour period, so you will need to leave your dog at the VMTH for up to two (2) nights.
  • **Weeks 2, 4, 8, 12, 16 & 20:** A physical examination, collection of blood and/or urine samples, and photographs of the lesions (NOTE: An overnight stay is not required).

Owner Responsibilities
• Bringing your dog in to scheduled appointments every 2 weeks for the first month and then monthly for the next four (4) months
• Giving your dog the prescribed drug as instructed by the UCD Dermatology Service
• Covering the cost of the skin biopsy and the office visit if the diagnosis is not confirmed to be PF

Benefits
• If the initial skin biopsy confirms the diagnosis of PF, the sponsor will pay for the cost of the skin biopsy and the office visit (as a credit to your account), and cover all other costs associated with this study as well as any expenses incurred as a result of adverse reactions to the drug (up to $4800). Additionally, upon completion, you will be compensated $200 for taking part in this study.
• Possible benefits for participation could include control of your dog’s PF while on the drug.
• Results from this study will hopefully lead a treatment for canine PF.